Tweets
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
4 years 8 months ago
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we break cycle by ⬆️adherence & health literacy, d/c smoking, use drug levels, biomarkers. Oh that in in future #ACR meetings! #ACR21 abst#1830 @RheumNow https://t.co/GyhgUGHWe8
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 8 months ago
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology​). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
Katie Poholek @kpoho ( View Tweet )
4 years 8 months ago
Similar effects in those with CKD stage 3, with also high proportion of achieving serum urate target <6mg/dL (overall 99% of study sample achieved target during trial) https://t.co/gKvDJKoWuw
Tuhina Neogi, MD, PhD @Tuhina_Neogi ( View Tweet )
4 years 8 months ago
Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY
Tuhina Neogi, MD, PhD @Tuhina_Neogi ( View Tweet )
4 years 8 months ago
OA oral session - abstract 1904
Devin Driscoll (mentor @tuhina_neogi) presenting data from MOST:
Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement
#ACR21 https://t.co/APZAJdHH5M
Rheum Cat @rheum_cat ( View Tweet )
4 years 8 months ago
Dr Ami Shah - Scleroderma & Cancer:
🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective?
🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below
#ACR21 #ACRambassador https://t.co/2VcWn2UInm
Didem Saygin, MD @didemsayginmd ( View Tweet )
4 years 8 months ago
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Janet Pope @Janetbirdope ( View Tweet )
4 years 8 months ago
Hair Loss due to Methotrexate from RCTs in RA estimated at 6.9%.
It's an understandable source of concern for those taking the medication
#ACR21 https://t.co/GymV2RC7jT
Dr Irwin Lim @_connectedcare ( View Tweet )
4 years 8 months ago
